Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or transfusion-dependent beta ...
Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune ...
Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or transfusion-dependent beta ...
Beta thalassemia major, also known as Cooley’s anemia and transfusion-dependent beta thalassemia, causes the body’s red blood ...
Can we predict—and prevent—why transplanted beta cells fail? A preclinical study titled “ChemPerturb-seq screen identifies a small molecule cocktail enhancing human beta cell survival after ...
People with type 1 diabetes must constantly rely on insulin injections or pumps, usually for the rest of their life after diagnosis. The autoimmune disease destroys the cells that produce the hormone, ...
Rapid advances in cell therapy have resulted in complex processes. As they move toward the clinic, manufacturers are attempting to scale up or scale out the processes using legacy equipment that often ...
USA: A team of scientists has developed a novel bioengineering platform that integrates flexible electronics into lab-grown pancreatic tissues, offering an unprecedented window into how insulin- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results